维普期刊资源整合服务平台（V6.5）

38篇 您的检索式：作者名="TOPP MS"

选中清除导出查看参考文献查看引证文献引用追踪共2页首页上一页第1页下一页末页 /2 跳转

	题名	作者	年代	出处	被引量
1	Targeted therapy with theT-cell-engaging antibody blinaturaomab of chemotherapy-refractoryminimal residual disease in B-lineage acute lymphoblastic leukemiapatients results in high response rate and prolonged leukemia-freesurvival 显示文摘	Topp MS Kufer P Gokbuget N	2011	J Clin Oncol2011，29，：	1
2	Targeted therapy withthe T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-Hneage acutelymphoblastic leukemia patients results in high response rate andprolonged leukemia-free survival显示文摘	Topp MS Kufer P Gokbuget N	2011	J Clin Oncol2011，29，18：	1
3	Long-term follow-up of hematologic relapse-free survival in a phase 2 study ofblinatumomab in patients with MRD in B-Iineage ALL显示文摘	Topp MS Gokbuget N Zugmaier G	2012	Blood2012，120，26：	1
4	Safety and activi- ty of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicenter, single- arm, phase 2 study 显示文摘	TOPP MS GOKBUGET N STEIN AS	2015	Lancet Oncol2015，16，1：	1
5	T-cell clones can be rendered specific for CD19:toward the selective augmentation of the graft-versus-B-lineage leukemia effect显示文摘	Cooper LJN Topp MS Serrano LM	2002	Blood2002，101，4：	1
6	Targeted therapy with the T-cell-engaging antibody blinatumomab of chemothera- pyrefractoryminimal residual disease in B-lineage acute lympho- blasticleukemia patients results in high response rate and pro- longedleukemia-free survival显示文摘	TOPP MS KUFER P GOKBUGET N	2011	J Clin 0ncoi2011，29，18：	1
7	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells显示文摘	Kowolik CM Topp MS Gonzalesz S	2006	Cancer Res2006，66，10：	1
8	Long-term follow-upof hematologic relapse-free survival in a phase 2 study of hlinatumomabin patients with MRD in B-lineage ALL 显示文摘	TOPP MS GOKBUGET N ZUGMAIER G	2012	Blood2012，120，26：	1
9	Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival显示文摘	Topp MS Kufer P Gkbuget N	2011	J Clin Oncol2011，29，18：	1
10	Phase II trial of theanti-CD19 bispecific T cell-engager blinatumomab showshe- matologic and molecular remissions in patients with relapsedor re- fractory B-precursor acute lymphoblastic leukemia 显示文摘	TOPP MS GOKBUGET N ZUGMAIER G	2014	J Clin Oncol2014，32，36：	1
11	A phase I study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma显示文摘	ROTHE A SASSE S TOPP MS	2015	Blood2015，125，26：	1
12	Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL显示文摘	Topp MS Gkbuget N Zugmaier G	2012	Blood2012，120，26：	1
13	Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia显示文摘	Zugmaier G Topp MS Alekar S	2014	Blood Cancer J2014，4，：	1
14	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and anti- tumor efficiency of adoptively transferred T cells 显示文摘	Kowolik CM Topp MS Gonzalez S	2006	Cancer Res2006，66，10：	1
15	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells显示文摘	Kowolik CM Topp MS Gonzalez S	2006	Cancer Res2006，66，10：	1
16	Phase lI trial of the anti-CD19 bispecificT cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia 显示文摘	Topp MS Gfkbuget N Zugmaier G	2014	J Clin Oncol2014，32，36：	1
17	CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells显示文摘	Kowolik CM Topp MS Gonzalez S	2006	Cancer Res2006，66，10：	1
18	CD28 eostimulation provided through a CD19-specifie chimeric antigen receptor en- hances in vivo persistence and antitumor efficacy of adoptively transferred T cells 显示文摘	Kowolik CM Topp MS Gonzalez S	2006	Cancer research2006，66，10：	1
19	Targeted therapy with the T-Cell-Engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-Lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival显示文摘	Topp MS Kufer P GOkbuget N	2011	J ClinOncol2011，29，18：	1
20	Long-term follow- up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL 显示文摘	Topp MS Gokbuget N Zugmaier G	2012	Blood2012，120，26：	1

返回顶部每页显示：

共2页首页上一页第1页下一页末页 /2 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示